US 2024/0207202 A1Published application

Combination therapies targeting mitochondrial biogenesis for cancer therapy

AssigneeThe Wistar Institute of Anatomy and Biology

InventorsGao Zhang, Qin Liu, Dario Carlo Altieri, Meenhard Herlyn

Life of this patent

Estimating the term…

Abstract

Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Claims1

Dependent claims

A pharmaceutical composition comprising a MAPK inhibitor and a reagent that downregulates or reduces TFAM, TRAP-1, PPRC1, or ESSRA.

Dependencies are inferred from the claim text.

Facts

Application: 18/534,114Filed 8 Dec 2023
Priority: 6 Aug 2015
Published: 27 Jun 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 31/06
Phenols: the aromatic ring being substituted by nitro groups
A61K 31/155
Amines: amidines , e.g. guanidine , isourea , isothiourea
A61K 31/245
Having an amino or nitro group: amino benzoic acid types, e.g. procaine, novocaine
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…

Family

Application62/201,788Us provisional application · filed 6 Aug 2015
Application15/750,318Continuation · filed 5 Feb 2018
Application17/834,667Continuation · filed 7 Jun 2022
Application18/534,114Continuation
US 2018/0228740 A1Published application
US 2023/0181489 A1Published application
US 2024/0207202 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results